Within the past decade, biology has been transformed from a lab science with individual scientists into a collaborative enterprise involving people with various domain expertise well beyond biology that includes chemistry, computer science, engineering, and mathematics.
This collaboration has generated vast amounts of disparate data to validate and prioritize the flood of new drug targets from genomic data. Moreover, supercomputing is the only means of converting this expansive data into knowledge that ultimately provides consumers with more effective drugs-eventually leading to personalized medicine.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
